New drug combo shows promise for Hard-to-Treat blood cancer
NCT ID NCT03467867
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests whether combining venetoclax (a pill) with rituximab (an injection) can shrink or control chronic lymphocytic leukemia (CLL) that has come back or stopped responding to other treatments. About 25 adults with CLL will receive this combination. The goal is to see how many people respond and how long the response lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.